안과 질환 치료제 시장 규모, 점유율, 성장 분석 : 질환 적응증별, 약물 종류별, 지역별 - 산업 예측(2025-2032년)
Ophthalmic Disease Therapeutics Market Size, Share, Growth Analysis, By Disease indication (Glaucoma, Retinal disease), By Drug Class (Anti-Inflammatory, Anti - infective), By Region - Industry Forecast 2025-2032
상품코드:1622423
리서치사:SkyQuest Technology Consulting Pvt. Ltd.
발행일:2024년 12월
페이지 정보:영문 157 Pages
라이선스 & 가격 (부가세 별도)
한글목차
2023년 안과 질환 치료제 시장 규모는 335억 달러로 2024년 355억 4,000만 달러에서 2032년 570억 8,000만 달러로 성장하여 예측 기간(2025-2032년) 동안 6.10%의 CAGR을 기록할 것으로 예상됩니다.
세계 안과 치료 시장은 안과 질환의 유병률 증가와 시력 관리에 대한 수요 증가에 힘입어 큰 폭의 성장세를 보이고 있습니다. 미국 국립 안과 연구소(National Eye Institute)는 시력 관련 질병이 미국 경제에 연간 약 1,390억 달러의 손실을 초래하고 있다고 밝혔습니다. 주요 제약사들은 망막 질환의 혁신적인 치료에 많은 투자를 하고 있으며, 가까운 시일 내에 더 진보된 치료법이 승인될 것으로 예상됩니다. 또한, 아시아 시장에서 비용 효율적인 시판 안과 약품의 등장은 세계 매출을 끌어올릴 가능성이 높습니다. 항염증제, 항감염제, 항VEGF제, 항녹내장 치료제가 시장을 주도하고 있으며, 항염증제는 2019년 27%의 점유율을 차지할 것으로 예상되며, 예측 기간 동안 선두를 유지할 것으로 예상됩니다.
목차
소개
조사 목적
조사 범위
정의
조사 방법
정보 조달
2차 데이터와 1차 데이터 방법
시장 규모 예측
시장 가정과 제한
주요 요약
세계 시장 전망
공급과 수요 동향 분석
부문별 기회 분석
시장 역학과 전망
시장 개요
시장 규모
시장 역학
성장 촉진요인과 기회
성장 억제요인과 과제
Porters 분석
주요 시장 인사이트
핵심성공요인
경쟁 정도
주요 투자 기회
시장 생태계
시장 매력 지수(2024년)
PESTEL 분석
거시경제 지표
밸류체인 분석
가격 분석
안과 질환 치료제 시장 규모 : 약물 종류별
시장 개요
항염증
항감염제
항VEGF
녹내장 예방
베타 차단제
프로스타글란딘 유사체
알파 아드레날린 작용제
탄산탈수효소 억제제
복합제
기타
기타
안과 질환 치료제 시장 규모 : 제형별
시장 개요
고체
액체
반고체
안과 질환 치료제 시장 규모 : 질환 적응증별
시장 개요
녹내장
개방각 녹내장
폐쇄각 녹내장
기타
안구건조증
망막 질환
당뇨병성 황반부종(DME)
황반변성증(AMD)
당뇨망막병증(DR)
망막정맥폐쇄증(RVO)
알레르기와 감염증
기타
안과 질환 치료제 시장 규모 : 유통 채널별
시장 개요
병원 약국
소매 약국과 온라인 약국
안과 질환 치료제 시장 규모
북미
미국
캐나다
유럽
독일
스페인
프랑스
영국
이탈리아
기타 유럽
아시아태평양
중국
인도
일본
한국
기타 아시아태평양
라틴아메리카
브라질
기타 라틴아메리카
중동 및 아프리카
GCC 국가
남아프리카공화국
기타 중동 및 아프리카
경쟁 정보
상위 5개사의 비교
주요 기업의 시장 포지셔닝(2024년)
주요 시장 기업이 채용한 전략
시장의 최근 동향
기업의 시장 점유율 분석(2024년)
주요 기업 개요
기업 개요
제품 포트폴리오 분석
부문별 점유율 분석
매출 전년비 비교(2022-2024)
주요 기업 개요
Novartis AG(Switzerland)
Roche Holding AG(Switzerland)
Regeneron Pharmaceuticals, Inc.(USA)
Allergan(part of AbbVie)(USA)
Bausch Health Companies Inc.(Canada)
Pfizer Inc.(USA)
Merck & Co., Inc.(USA)
Santen Pharmaceutical Co., Ltd.(Japan)
Teva Pharmaceutical Industries Ltd.(Israel)
Otsuka Pharmaceutical Co., Ltd.(Japan)
Alcon Inc.(Switzerland)
Aerie Pharmaceuticals, Inc.(USA)
Omeros Corporation(USA)
Kodiak Sciences Inc.(USA)
EyePoint Pharmaceuticals, Inc.(USA)
Johnson & Johnson(USA)
Abbott Laboratories(USA)
Carl Zeiss Meditec AG(Germany)
Topcon Corporation(Japan)
Hoya Corporation(Japan)
결론과 추천사항
ksm
영문 목차
영문목차
Ophthalmic Disease Therapeutics Market size was valued at USD 33.5 Billion in 2023 and is poised to grow from USD 35.54 Billion in 2024 to USD 57.08 Billion by 2032, growing at a CAGR of 6.10% during the forecast period (2025-2032).
The global market for ophthalmic therapeutics is set for significant growth, driven by the rising incidence of ocular diseases and an escalating demand for vision care. The National Eye Institute highlights that vision-related ailments cost the U.S. economy approximately $139 billion annually. Major pharmaceutical firms are heavily investing in innovative therapies for retinal disorders, with more advanced treatments expected to gain approval in the near future. Additionally, the advent of cost-effective over-the-counter ophthalmic drugs in Asian markets is likely to boost global revenues. Anti-inflammatory, anti-infectives, anti-VEGF, and anti-glaucoma treatments dominate the market, with anti-inflammatory drugs capturing a substantial 27% share in 2019 and expected to maintain a leading position throughout the forecast period.
Top-down and bottom-up approaches were used to estimate and validate the size of the Ophthalmic Disease Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Ophthalmic Disease Therapeutics Market is segmented by Drug Class, Dosage Form, Disease Indication, Distribution Channel and region. Based on Drug Class, the market is segmented into anti-inflammatory, anti-infectives, Anti-VEGF, anti-glaucoma and others. Based on Dosage Form, the market is segmented into solid, liquid and semisolid. Based on Disease Indication, the market is segmented into glaucoma, dry eye disease, retinal diseases, allergy & infections and others. Based on Distribution Channel, the market is segmented into hospital pharmacies and retail & online pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Ophthalmic Disease Therapeutics Market
The growth of the ophthalmic disease therapeutics market is significantly driven by the increasing presence of small and mid-sized companies that are diversifying the competitive landscape. Key industry players, including Allergan plc, F. Hoffmann-La Roche AG, and Regeneron Pharmaceuticals, Inc., compete alongside these smaller entities, leading to a fragmented market. This competition fosters innovation and the development of new treatment options for prevalent ophthalmic conditions such as macular degeneration, macular edema, and retinal vein occlusion. Established treatments like Eylea from Regeneron and Lucentis from F. Hoffmann-La Roche continue to play pivotal roles in effectively managing these diseases, further stimulating market expansion.
Restraints in the Ophthalmic Disease Therapeutics Market
The Ophthalmic Disease Therapeutics market faces significant constraints primarily due to the extended timelines required for the manufacturing and formulation of ophthalmic medications. Additionally, the potential side effects associated with these drugs pose another challenge that could hinder market expansion during the forecast period. The complexity of developing these treatments, coupled with the need for thorough testing and regulatory approvals, often results in delays that may deter investment and innovation in this sector. Consequently, these factors are anticipated to limit the overall growth potential of the ophthalmic therapeutics market in the foreseeable future.
Market Trends of the Ophthalmic Disease Therapeutics Market
The Ophthalmic Disease Therapeutics market is witnessing a robust trend driven by rapid technological advancements in ophthalmology, particularly in imaging techniques and surgical tools that enhance patient outcomes. Innovations such as femtosecond lasers in cataract surgery exemplify the shift towards more precise and safer procedures, minimizing complications and improving recovery times. Additionally, the integration of artificial intelligence in diagnostic tools is streamlining patient assessments, allowing for earlier detection and personalized treatment approaches. As a result, these developments are attracting investment and market interest, thereby fostering growth and significantly enhancing the overall landscape of ophthalmic disease management.
Table of Contents
Introduction
Objectives of the Study
Scope of the Report
Definitions
Research Methodology
Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations
Executive Summary
Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis
Market Dynamics & Outlook
Market Overview
Market Size
Market Dynamics
Drivers & Opportunities
Restraints & Challenges
Porters Analysis
Competitive rivalry
Threat of substitute
Bargaining power of buyers
Threat of new entrants
Bargaining power of suppliers
Key Market Insights
Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Global Ophthalmic Disease Therapeutics Market Size by Drug Class & CAGR (2025-2032)
Market Overview
Anti-Inflammatory
Anti-Infectives
Anti-VEGF
Anti-Glaucoma
Beta Blockers
Prostaglandins Analogs
Alpha Adrenergic Agonists
Carbonic Anhydrase Inhibitors
Combination Drugs
Others
Others
Global Ophthalmic Disease Therapeutics Market Size by Dosage Form & CAGR (2025-2032)
Market Overview
Solid
Liquid
Semisolid
Global Ophthalmic Disease Therapeutics Market Size by Disease Indication & CAGR (2025-2032)
Market Overview
Glaucoma
Open Angle Glaucoma
Angle Closure Glaucoma
Others
Dry Eye Disease
Retinal Diseases
Diabetic Macular Edema (DME)
Macular Degeneration (AMD)
Diabetic Retinopathy (DR)
Retinal Vein Occlusion (RVO)
Allergy & Infections
Others
Global Ophthalmic Disease Therapeutics Market Size by Distribution Channel & CAGR (2025-2032)
Market Overview
Hospital Pharmacies
Retail & Online Pharmacies
Global Ophthalmic Disease Therapeutics Market Size & CAGR (2025-2032)
North America (Drug Class, Dosage Form, Disease Indication, Distribution Channel)
US
Canada
Europe (Drug Class, Dosage Form, Disease Indication, Distribution Channel)
Germany
Spain
France
UK
Italy
Rest of Europe
Asia Pacific (Drug Class, Dosage Form, Disease Indication, Distribution Channel)
China
India
Japan
South Korea
Rest of Asia-Pacific
Latin America (Drug Class, Dosage Form, Disease Indication, Distribution Channel)
Brazil
Rest of Latin America
Middle East & Africa (Drug Class, Dosage Form, Disease Indication, Distribution Channel)
